Disease · MONDO_0005502
dengue disease
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. dengue disease. Diseases, record MONDO_0005502. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005502
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
DENV infection, DF, Dengue, Dengue fever, Dengue virus caused disease or disorder, Dengue virus disease or disorder, Dengue virus infection, Dengue virus infectious disease, break bone fever, breakbone fever, classic dengue
- Open Targets
Drugs20
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ACETYLCYSTEINE | CHEMBL600 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALBUMIN HUMAN | CHEMBL1201451 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BARICITINIB | CHEMBL2105759 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EMETINE HYDROCHLORIDE | CHEMBL493439 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MONTELUKAST | CHEMBL787 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MOSNODENVIR | CHEMBL5314530 | Small molecule | Phase 2 | ClinicalTrials.gov and TTD | 3 | 1 | 1 | Drugs and targets |
| FENRETINIDE | CHEMBL7301 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IC14 | CHEMBL2109330 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| IVERMECTIN | CHEMBL6067487 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 20
See all 20 drugsTargets62
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CD14 | Monocyte differentiation antigen CD14 | 1 | Monocyte differentiation antigen CD14 inhibitor | Phase 2 | https://conductscience.org/library/genes/929 | Drugs and targets |
| COXFA4 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 1/2 | https://conductscience.org/library/genes/4697 | Drugs and targets |
| COXFA4L2 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 1/2 | https://conductscience.org/library/genes/56901 | Drugs and targets |
| CYSLTR1 | Cysteinyl leukotriene receptor 1 | 1 | Cysteinyl leukotriene receptor 1 antagonist | Phase 2/3 | https://conductscience.org/library/genes/10800 | Drugs and targets |
| GAA | Alpha glucosidase | 1 | Alpha glucosidase inhibitor | Phase 1/2 | https://conductscience.org/library/genes/2548 | Drugs and targets |
| GPD2 | Glycerol-3-phosphate dehydrogenase, mitochondrial | 1 | Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor | Phase 1/2 | https://conductscience.org/library/genes/2820 | Drugs and targets |
| JAK1 | Tyrosine-protein kinase JAK1 | 1 | Tyrosine-protein kinase JAK1 inhibitor | Phase 3 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Tyrosine-protein kinase JAK2 | 1 | Tyrosine-protein kinase JAK2 inhibitor | Phase 3 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| MGAM | Alpha glucosidase | 1 | Alpha glucosidase inhibitor | Phase 1/2 | https://conductscience.org/library/genes/8972 | Drugs and targets |
| MGAM2 | Alpha glucosidase | 1 | Alpha glucosidase inhibitor | Phase 1/2 | https://conductscience.org/library/genes/93432 | Drugs and targets |
1 to 10 of 62
See all 62 targetsTrials17
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04906980 | A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever | Phase 2 | 5 | 2024-03-01 | Dengue | MOSNODENVIR | Its record names the disease | ClinicalTrials.gov |
| NCT07543458 | Therapeutics for Moderate and Severe Dengue | Phase 3 | 8,800 | Dengue, Severe Dengue, Mosquito-Borne Diseases, Vector Borne Diseases, Arbovirus Infections, Flavivirus Infections, RNA Virus Infections, Hemorrhagic Fever | ACETYLCYSTEINE, BARICITINIB, DEXAMETHASONE | Its record names the disease | ClinicalTrials.gov | |
| NCT07016321 | Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative) | Phase 2/3 | 600 | Dengue | EMETINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT06551844 | Adaptive Dengue Antiviral Platform Trial | Phase 2 | 500 | Dengue, Antiviral Drugs | MOLNUPIRAVIR, REMDESIVIR | Its record names the disease | ClinicalTrials.gov | |
| NCT05631405 | Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone (DengDex Study) | Not applicable | 200 | Severe Dengue | DEXAMETHASONE | Its record names the disease | ClinicalTrials.gov | |
| NCT05034809 | Effectiveness Of High Dose Melatonin As Adjunctive Therapy For Dengue Fever With Warning Signs | Phase 2 | 140 | Dengue Fever With Warning Signs | MELATONIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04377451 | Metformin in Dengue With Obesity | Phase 1/2 | 120 | Dengue, Viral Infection, Metformin, Anti-inflammatory Agents, Obesity, Overweight | METFORMIN | Its record names the disease | ClinicalTrials.gov | |
| NCT06917001 | Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2) | Phase 2 | 120 | Dengue Fever | RESOMELAGON | Its record names the disease | ClinicalTrials.gov | |
| NCT04076254 | Resuscitation With Albumin 5% in Dengue Haemorrhagic Fever | Phase 3 | 84 | Dengue Hemorrhagic | ALBUMIN HUMAN | Its record names the disease | ClinicalTrials.gov | |
| NCT06747130 | Efficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients | Phase 2/3 | 82 | Dengue, Montelukast, Transaminases | MONTELUKAST | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 17
See all 17 trialsComparisons in its trials7
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| JNJ-64281802 vs Placebo: Number of Participants With Clinically Significant Abnormalities in Vital Signs | 1 of 2 | 0 of 3 | 5 | NCT04906980 | Trial comparisons |
| JNJ-64281802 vs Placebo: Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Findings | 0 of 2 | 0 of 3 | 5 | NCT04906980 | Trial comparisons |
| JNJ-64281802 vs Placebo: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 2 of 2 | 3 of 3 | 5 | NCT04906980 | Trial comparisons |
| JNJ-64281802 vs Placebo: Number of Participants With Clinically Significant Abnormalities in Physical Examination | 0 of 2 | 1 of 3 | 5 | NCT04906980 | Trial comparisons |
| JNJ-64281802 vs Placebo: deaths from any cause | 0 of 2 | 0 of 3 | 5 | NCT04906980 | Trial comparisons |
| JNJ-64281802 vs Placebo: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters | 2 of 2 | 3 of 3 | 5 | NCT04906980 | Trial comparisons |
| JNJ-64281802 vs Placebo: serious adverse events | 0 of 2 | 0 of 3 | 5 | NCT04906980 | Trial comparisons |
Papers from its trials26
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005502
GET https://conductscience.org/api/diseases/v1/MONDO_0005502/targets?page=2